Preclinical

ForwardVue

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

ForwardVue Pharma Secures Funding to Advance Pre-Clinical Development Programs

Lead Product(s): Caroboxyamidotriazole

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding August 26, 2020

Details:

ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Emerald Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO

Lead Product(s): Tetrahydrocannabinol

Therapeutic Area: Ophthalmology Product Name: NB-1111

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

Emerald Bioscience is working to complete the final preclinical steps for NB-1111, its promising glaucoma product candidate, and preparing for first human study in Australia.

Retrotope

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and Related Retinal Pathologies

Lead Product(s): Docosahexaenoic Acids

Therapeutic Area: Ophthalmology Product Name: RT011

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.

TALLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Lead Product(s): TA-A001

Therapeutic Area: Ophthalmology Product Name: TA-A001

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

Patent covers the chemical composition of SmartCelle polymers, their method of manufacture and their ability to form 20nm-30nm stable drug-loaded dynamic micelles in aqueous solution. SmartCelle formulations comprising a number of anti-inflammatory drugs are presented.

Biogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Biogen Joins Harvard in Gene Therapy Pact to Fight Eye Disease

Lead Product(s): AAV gene therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Massachusetts Eye and Ear

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 06, 2020

Details:

The gene at the center of the new agreement, PRPF31, has been linked to autosomal dominant retinitis pigmentosa. PRPF31 mutations are believed to cause an estimated 25% of all retinitis pigmentosa cases.

AsclepiX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AsclepiX Therapeutics Announces $35 Million Series A Financing

Lead Product(s): AXT107

Therapeutic Area: Ophthalmology Product Name: AXT107

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund

Deal Size: Undisclosed Upfront Cash: $35.0 million

Deal Type: Series A Financing June 24, 2020

Details:

Proceeds will be used to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials.

Rezolute

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

Lead Product(s): RZ402

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

RZ402 demonstrated an excellent ADME (absorption, distribution, metabolism and excretion) profile, and moderate renal clearance with plasma levels remained above EC50 for 24 hours after dosing, consistent with a daily oral dose regimen.

Samsung Bioepis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

SB15 received the green light from health authorities in eight countries, including phase three clinical trials in South Korea and the United States. SB15 is a biosimilar candidate of Regeneron Pharmaceuticals' Eylea, to treat age-related (wet) macular degeneration (AMD).

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

InMed Releases CBN Preclinical Results in Glaucoma

Lead Product(s): Cannabinol

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.

CDR Life

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy

Lead Product(s): Antibody fragment-based therapeutics

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: $494.0 million

Deal Type: Licensing Agreement May 13, 2020

Details:

Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

ForwardVue

ForwardVue Pharma Secures Funding to Advance Pre-Clinical Development Programs

Emerald Bioscience

Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO

Retrotope

Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and Related Retinal Pathologies

TALLC

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Biogen

Biogen Joins Harvard in Gene Therapy Pact to Fight Eye Disease

AsclepiX Therapeutics

AsclepiX Therapeutics Announces $35 Million Series A Financing

Rezolute

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

Samsung Bioepis

Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets

InMed Pharmaceuticals

InMed Releases CBN Preclinical Results in Glaucoma

CDR Life

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy